GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » Cyclically Adjusted Revenue per Share

Theratechnologies (Theratechnologies) Cyclically Adjusted Revenue per Share : $2.65 (As of Feb. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Theratechnologies's adjusted revenue per share for the three months ended in Feb. 2024 was $0.329. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.65 for the trailing ten years ended in Feb. 2024.

During the past 12 months, Theratechnologies's average Cyclically Adjusted Revenue Growth Rate was 11.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Theratechnologies was 20.30% per year. The lowest was 1.80% per year. And the median was 16.40% per year.

As of today (2024-06-10), Theratechnologies's current stock price is $1.22. Theratechnologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 was $2.65. Theratechnologies's Cyclically Adjusted PS Ratio of today is 0.46.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Theratechnologies was 40.47. The lowest was 0.35. And the median was 6.62.


Theratechnologies Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Theratechnologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Cyclically Adjusted Revenue per Share Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.56 1.74 2.08 2.30 2.67

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.42 2.70 2.74 2.67 2.65

Competitive Comparison of Theratechnologies's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Theratechnologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Cyclically Adjusted PS Ratio falls into.



Theratechnologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theratechnologies's adjusted Revenue per Share data for the three months ended in Feb. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=0.329/125.4675*125.4675
=0.329

Current CPI (Feb. 2024) = 125.4675.

Theratechnologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201405 0.145 99.394 0.183
201408 0.000 99.315 0.000
201411 0.140 99.078 0.177
201502 0.239 99.078 0.303
201505 0.384 100.263 0.481
201508 0.446 100.579 0.556
201511 0.385 100.421 0.481
201602 0.393 100.421 0.491
201605 0.421 101.765 0.519
201608 0.414 101.686 0.511
201611 0.417 101.607 0.515
201702 0.385 102.476 0.471
201705 0.406 103.108 0.494
201708 0.477 103.108 0.580
201711 0.498 103.740 0.602
201802 0.433 104.688 0.519
201805 0.509 105.399 0.606
201808 0.690 106.031 0.816
201811 0.729 105.478 0.867
201902 0.785 106.268 0.927
201905 0.812 107.927 0.944
201908 0.837 108.085 0.972
201911 0.852 107.769 0.992
202002 0.817 108.559 0.944
202005 0.892 107.532 1.041
202008 0.730 108.243 0.846
202011 0.993 108.796 1.145
202102 0.729 109.745 0.833
202105 0.753 111.404 0.848
202108 0.752 112.668 0.837
202111 0.789 113.932 0.869
202202 0.780 115.986 0.844
202205 0.810 120.016 0.847
202208 0.875 120.569 0.911
202211 0.896 121.675 0.924
202302 0.823 122.070 0.846
202305 0.725 124.045 0.733
202308 0.862 125.389 0.863
202311 0.717 125.468 0.717
202402 0.329 125.468 0.329

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Theratechnologies  (NAS:THTX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Theratechnologies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.22/2.65
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Theratechnologies was 40.47. The lowest was 0.35. And the median was 6.62.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Theratechnologies Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (Theratechnologies) Business Description

Industry
Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.